Talk:Durvalumab
Appearance
This is the talk page for discussing improvements to the Durvalumab article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Durvalumab.
|
CD80 blocking
[edit]Is there any evidence that Durvalumab affects CD80 signaling pathways? It is in the article and I don't know where the evidence for that is. I'm wondering if the author just confused B7H1 (PD-L1) with B7.1 (CD80). Pulliam.thomas (talk) 05:24, 23 October 2018 (UTC)